Patents by Inventor Joost Cornelis Marinus UITDEHAAG
Joost Cornelis Marinus UITDEHAAG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220056540Abstract: A method for identifying a tumor that is susceptible to treatment with a TTK inhibitor, including: a) providing a sample of a tumor; b) determining the presence of a mutated CTNNB1 gene in the sample, wherein the mutation is located in exon 3 of CTNNB1 and the presence of a mutated CTNNB1 gene indicates the tumor is susceptible to treatment with a TTK inhibitor. Alternatively, step b) is replaced by the step of determining the presence of a mutated CTNNB1 protein in the sample, wherein the mutation is located in exon 3 of CTNNB1 and the presence of a mutated CTNNB1 protein indicates the tumor is susceptible to treatment with a TTK inhibitor. In a further alternative, step b) includes determining an altered expression of a CTNNB1 regulated gene, whereby an altered expression of a CTNNB1 regulated gene indicates the tumor is susceptible to treatment with a TTK inhibitor.Type: ApplicationFiled: November 9, 2021Publication date: February 24, 2022Applicant: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.Inventors: Jeroen DE ROOS, Joost Cornelis Marinus UITDEHAAG, Adrianus Petrus Antonius DE MAN, Rogier Christiaan BUIJSMAN, Guido Jenny Rudolf ZAMAN
-
Patent number: 11208696Abstract: A method for identifying a tumor that is susceptible to treatment with a TTK inhibitor, including: a) providing a sample of a tumor; b) determining the presence of a mutated CTNNB1 gene in the sample, wherein the mutation is located in exon 3 of CTNNB1 and the presence of a mutated CTNNB1 gene indicates the tumor is susceptible to treatment with a TTK inhibitor. Alternatively, step b) is replaced by the step of determining the presence of a mutated CTNNB1 protein in the sample, wherein the mutation is located in exon 3 of CTNNB1 and the presence of a mutated CTNNB1 protein indicates the tumor is susceptible to treatment with a TTK inhibitor. In a further alternative, step b) includes determining an altered expression of a CTNNB1 regulated gene, whereby an altered expression of a CTNNB1 regulated gene indicates the tumor is susceptible to treatment with a TTK inhibitor.Type: GrantFiled: April 14, 2016Date of Patent: December 28, 2021Assignee: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.Inventors: Jeroen De Roos, Joost Cornelis Marinus Uitdehaag, Adrianus Petrus Antonius De Man, Rogier Christiaan Buijsman, Guido Jenny Rudolf Zaman
-
Patent number: 11053230Abstract: The invention relates to a compound of Formula (I): Formula (I), or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.Type: GrantFiled: August 30, 2018Date of Patent: July 6, 2021Inventors: Adrianus Petrus Antonius De Man, Joost Cornelis Marinus Uitdehaag, Jan Gerard Sterrenburg, Joeri Johannes Petrus De Wit, Freek Van Cauter, Nicole Wilhelmina Cornelia Seegers, Antonius Maria Van Doornmalen, Rogier Christian Buijsman, Guido Jenny Rudolf Zaman
-
Patent number: 10689343Abstract: The invention relates to a compound of Formula I: Formula I, or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of tryptophan 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of cancer and central nervous system disease or disorder, either as a single agent or in combination with other therapies.Type: GrantFiled: July 11, 2017Date of Patent: June 23, 2020Assignee: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.Inventors: Adrianus Petrus Antonius De Man, Joost Cornelis Marinus Uitdehaag, Jan Gerard Sterrenburg, Joeri Johannes Petrus De Wit, Nicole Wilhelmina Cornelia Seegers, Antonius Maria Van Doornmalen, Rogier Christian Buijsman, Guido Jenny Rudolf Zaman
-
Publication number: 20200181128Abstract: The invention relates to a compound of Formula (I): Formula (I), or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.Type: ApplicationFiled: August 30, 2018Publication date: June 11, 2020Applicant: Netherlands Translational Research Center B.V.Inventors: Adrianus Petrus Antonius De Man, Joost Cornelis Marinus Uitdehaag, Jan Gerard Sterrenburg, Joeri Johannes Petrus De Wit, Freek Van Cauter, Nicole Wilhelmina Cornelia Seegers, Antonius Maria Van Doornmalen, Rogier Christian Buijsman, Guido Jenny Rudolf Zaman
-
Patent number: 10494360Abstract: A compound of Formula I: or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.Type: GrantFiled: March 8, 2017Date of Patent: December 3, 2019Assignee: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.VInventors: Adrianus Petrus Antonius De Man, Joost Cornelis Marinus Uitdehaag, Jan Gerard Sterrenburg, Joeri Johannes Petrus De Wit, Nicole Wilhelmina Cornelia Seegers, Antonius Maria Van Doornmalen, Rogier Christian Buijsman, Guido Jenny Rudolf Zaman
-
Publication number: 20190315688Abstract: The invention relates to a compound of Formula I: Formula I, or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of tryptophan 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of cancer and central nervous system disease or disorder, either as a single agent or in combination with other therapies.Type: ApplicationFiled: July 11, 2017Publication date: October 17, 2019Applicant: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.Inventors: Adrianus Petrus Antonius De Man, Joost Cornelis Marinus Uitdehaag, Jan Gerard Sterrenburg, Joeri Johannes Petrus De Wit, Nicole Wilhelmina Cornelia Seegers, Antonius Maria Van Doornmalen, Rogier Christian Buijsman, Guido Jenny Rudolf Zaman
-
Publication number: 20190211401Abstract: A method for identifying a tumor that is susceptible to treatment with a TTK inhibitor, including: a) providing a sample of a tumor; b) determining the presence of a mutated CTNNB1 gene in the sample, wherein the mutation is located in exon 3 of CTNNB1 and the presence of a mutated CTNNB1 gene indicates the tumor is susceptible to treatment with a TTK inhibitor. Alternatively, step b) is replaced by the step of determining the presence of a mutated CTNNB1 protein in the sample, wherein the mutation is located in exon 3 of CTNNB1 and the presence of a mutated CTNNB1 protein indicates the tumor is susceptible to treatment with a TTK inhibitor. In a further alternative, step b) includes determining an altered expression of a CTNNB1 regulated gene, whereby an altered expression of a CTNNB1 regulated gene indicates the tumor is susceptible to treatment with a TTK inhibitor.Type: ApplicationFiled: April 14, 2016Publication date: July 11, 2019Applicant: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.Inventors: Jeroen DE ROOS, Joost Cornelis Marinus UITDEHAAG, Adrianus Petrus Antonius DE MAN, Rogier Christiaan BUIJSMAN, Guido Jenny Rudolf ZAMAN
-
Publication number: 20190055213Abstract: A compound of Formula I: or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxygenase. The invention also relates to the use of the compounds of Formula (I) for the treatment or prevention of diseases cancer, infections, central nervous system disease or disorder, and immune-related disorders, either as a single agent or in combination with other therapies.Type: ApplicationFiled: March 8, 2017Publication date: February 21, 2019Applicant: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.Inventors: Adrianus Petrus Antonius DE MAN, Joost Cornelis Marinus UITDEHAAG, Jan Gerard STERRENBURG, Joeri Johannes Petrus DE WIT, Nicole Wilhelmina Cornelia SEEGERS, Antonius Maria VAN DOORNMALEN, Rogier Christian BUIJSMAN, Guido Jenny Rudolf ZAMAN
-
Patent number: 9856258Abstract: A compound of Formula I: wherein, R1 and R2 independently are selected from the group consisting of optionally substituted (6-10C)aryl and (1-5C)heteroaryl groups. The compounds can be used in pharmaceutical compositions, in particular in the treatment of cancer.Type: GrantFiled: March 30, 2015Date of Patent: January 2, 2018Assignee: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.Inventors: Adrianus Petrus Antonius De Man, Rogier Christian Buijsman, Jan Gerard Sterrenburg, Joost Cornelis Marinus Uitdehaag, Joeri Johannes Petrus De Wit, Guido Jenny Rudolf Zaman
-
Publication number: 20170096432Abstract: A compound of Formula I: wherein, R1 and R2 independently are selected from the group consisting of optionally substituted (6-10C)aryl and (1-5C)heteroaryl groups. The compounds can be used in pharmaceutical compositions, in particular in the treatment of cancer.Type: ApplicationFiled: March 30, 2015Publication date: April 6, 2017Applicant: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.Inventors: Adrianus Petrus Antonius DE MAN, Rogier Christian BUIJSMAN, Jan Gerard STERRENBURG, Joost Cornelis Marinus UITDEHAAG, Joeri Johannes Petrus DE WIT, Guido Jenny Rudolf ZAMAN
-
Patent number: RE48974Abstract: A compound of Formula I: wherein, R1 and R2 independently are selected from the group consisting of optionally substituted (6-10C)aryl and (1-5C)heteroaryl groups. The compounds can be used in pharmaceutical compositions, in particular in the treatment of cancer.Type: GrantFiled: December 27, 2019Date of Patent: March 15, 2022Assignee: NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V.Inventors: Adrianus Petrus Antonius De Man, Rogier Christian Buijsman, Jan Gerard Sterrenburg, Joost Cornelis Marinus Uitdehaag, Joeri Johannes Petrus De Wit, Guido Jenny Rudolf Zaman